IN VIVO CRO MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, request sample copy

North America has dominated the global in vivo CRO market for several years. The region is expected to account for 41.2% of the market share in 2024. This region is home to several top pharmaceutical companies who outsource a major portion of their preclinical research activities. With a strong presence of CROs catering to the life sciences industry and high investments in R&D, North America provides ideal conditions for growth of this market. The region also has stringent regulations for product testing and development which drives demand for specialized preclinical services. Several global players have established their headquarters and major facilities in the U.S. and Canada to leverage the skilled workforce and expertise available. This has ensured that North America remains the primary export and import hub for in vivo CRO services internationally.

The Asia Pacific region is poised to be the fastest growing market in the coming years. Countries like China, India, and South Korea offer lower operational costs compared to mature markets, attracting several pharmaceutical giants to outsource their preclinical work to Asia Pacific. This has encouraged local and international CROs to expand their footprint in the region to capture a share of the outsourced business. The economic development of Asia Pacific countries has also led to greater healthcare investments and a focus on developing domestic life sciences capabilities. This is increasing the demand for specialized in vivo services to support drug development programs within the region. With growing expertise, a large talent pool and proximity to resource-rich nations, Asia Pacific is well positioned to take over as the dominant outsourcing destination for global in vivo CRO requirements.